LB Pharmaceuticals Inc (LBRX) Financial Statements
Free cash flow over the same period: -$82.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LBRXLB Pharmaceuticals IncFollow LBRX — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 51.2 | 16.7 | 69.7 | |
| Pre-tax income | -63.1 | -25.2 | -85.7 | |
| Income tax | 0.0 | 0.0 | 0.0 | |
| Net income | -63.1 | -25.2 | -85.7 | |
| Diluted EPS ($) | -176.15 | -3.13 | -2.83 | |
| Diluted shares (mn) | — | 8.0 | — |
USD millions · SEC XBRL
LB Pharmaceuticals Inc — questions
- What is LB Pharmaceuticals Inc's net income?
- -$85.7M over the twelve months to 2026-06-30.
- What is LB Pharmaceuticals Inc's free cash flow?
- -$82.8M over the twelve months to 2026-06-30.
- What are LB Pharmaceuticals Inc's diluted earnings per share?
- $-2.83 over the twelve months to 2026-06-30.
Every figure on this page comes from LB Pharmaceuticals Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.